NEW YORK (October 31, 2013) Ariad Pharmaceuticals says it is suspending sales of its leukemia drug Iclusig because of concerns that patients could suffer from blood clots.
The Cambridge, Mass., company said the U.S. Food and Drug Administration asked it to stop marketing the drug Wednesday afternoon.
The company said Thursday it is negotiating with the FDA about changes to prescribing information and new ways to manage the risks associated with Iclusig.
Ariad said it wants to resume marketing the drug.
In December the FDA approved Iclusig as a treatment for two rare types of leukemia.